Amit Mittal on Scaling Yokogawa’s Life Science Ambitions in China

Since arriving in China in 2022 and relocating to Shanghai in 2024, Mittal has focused on bridging the gap between Yokogawa’s global heritage and the specific demands of the Chinese market. The division has already secured partnerships with prestigious institutions, including Peking University and Tsinghua University, by offering advanced confocal scanner technology and responsive, personalized development support.

For Mittal, success hinges on a localization strategy that extends beyond mere sales. By pushing for local manufacturing and fostering a collaborative ecosystem, the company aims to support the entire drug development cycle. With a team of roughly 20 professionals, he maintains that the division’s competitive edge is found in its commitment to business ethics and long-term sustainability rather than just market scale. “Customers are not only buying a product; they are also buying the people and the support behind it,” Mittal notes, emphasizing that internal culture remains the primary driver of the company’s external performance.